Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

KORU Medical Systems, Inc. Common Stock (DE)

KRMD

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

Last trade $3.53
Day change -$0.16 (-4.34%)
Day range $3.49 – $3.74
Volume 81,114
Market cap $160M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$160.05M
Price / earnings
—
Price / book
8.25×
Price / sales
3.46×
EV / sales
3.31×
EV / EBITDA
770.49×

Profitability

Earnings per share
-$0.02
Return on assets
-2.86%
Return on equity
-4.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.03×
Current ratio
2.97×
Quick ratio
2.27×
Cash ratio
1.08×

Cash flow

Price / cash flow
361.54×
Price / free cash flow
—
Free cash flow
-$387.37K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KRMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$11.57M$12.05M$11.76M$10.9M$10.4M$10.19M$9.64M$8.84M
Cost of revenue$4.02M$4.2M$4.53M$4.08M$4.14M$3.72M$3.59M$3.28M
Gross profit$7.55M$7.85M$7.23M$6.82M$6.26M$6.48M$6.05M$5.56M
Selling, general and administrative$5.87M$5.94M$6.58M$6.04M$5.99M$5.38M$5.96M$5.83M
Research and development$1.28M$1.07M$1.32M$1.14M$933.11K$1.19M$1.11M$1.11M
Total operating expenses$7.36M$7.22M$8.1M$7.36M$7.13M$6.79M$7.29M$7.15M
Operating income$187.12K$626.99K-$864.92K-$547.1K-$867.68K-$312.66K-$1.25M-$1.59M
Interest expense$60.74K$59.87K$81K$0$74.57K$78.95K$73.18K$0
Income before taxes$236.1K$258.25K-$807.08K-$482.17K-$778.12K-$189.51K-$1.17M-$1.56M
Income taxes$18K$5.8K$0$4.68K-$150$17.36K$0$2.89K
Net income$218.1K$252.45K-$807.08K-$486.86K-$777.97K-$206.87K-$1.17M-$1.56M
Net income attributable to common shareholders$218.1K$252.45K-$807.08K-$486.86K-$777.97K-$206.87K-$1.17M-$1.56M
EBITDA$397.14K$837.02K-$667.39K-$367.93K-$663.2K-$103.17K-$1.03M-$1.38M
Basic earnings per share$0.00$0.01-$0.02-$0.01-$0.02$0.00-$0.03-$0.03
Diluted earnings per share$0.00$0.01-$0.02-$0.01-$0.02$0.00-$0.03-$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Reasons to Retain Doximity Stock in Your Portfolio for Now

Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth.

GlobeNewswire Inc.

Cirtec Medical Announces Appointment of New Chief Executive Officer

Cirtec Medical has appointed Shar Matin as its new CEO, effective September 2, 2025. Matin brings over 25 years of global leadership experience in medical technology, previously serving as CEO of Cordis and holding executive roles at multiple medical technology companies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.